Myval THV matches SAPIEN and Evolut THVs in 30-day outcomes, supporting its role in severe aortic stenosis treatment.

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued strong ...

According to Caranx, TAVI/TAVR is ... device giant Edwards Lifesciences recently reported that patients were experiencing ...

a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences ... Aortic Valve Replacement (“TAVR”) platform ...

Patients who underwent transcatheter aortic valve replacement with a SAPIEN 3 (S3) THV had documented 3 cusp and cusp overlap views, and post-implant computed tomography was identified. THV expansion ...

In a second case of acute aortic rupture, which again followed an Edwards SAPIEN implantation and led to tamponade with rapid hemodynamic collapse, implantation of a second 'valve-in-valve' system ...

Such an approval would also widen Edwards’ share in the TAVR market. The company, already a leader with its Sapien valves, agreed to acquire JenaValve as part of a $1.2 billion double M&A swoop ...

In their assessment, Wolfe Research analysts cited a six-year data point from November that raised fresh worries about the TAVR market and Edwards ... particularly in transcatheter valve therapies.